Abiopharma

🔍 Scheiner Zachary (Director)

Company: LENZ Therapeutics, Inc. (LENZ)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 22,100 shares of Stock Option (right to buy) at $6.63 per share (Derivative)
  Date: 2026-06-15 | Code: A | Expires: 2036-06-15 | equity_swap_involved: 0 | shares_owned_after: 22,100.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
• F2: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.